


## Drugs used in peptic ulcer



### Objectives:

- Classify the main different classes of hypo-secretory drugs used for treating peptic ulcer.
- Know the characteristic pharmacokinetics, pharmacodynamics and side effects of proton pump inhibitors, and H2 receptor blockers.
- Know the cyto-protective drugs mainly misoprostol and its use in NSAIDs-induced peptic ulcer.
- Identify different antacids that are used to relief pain of peptic ulcer.

### Done by:

- Atheer Alnashwan
- **MCQs:** Khalid Aburas
- **Revision:** Qusay Ajlan, Atheer Alnashwan

### Editing file

Revised by	
خولة العماري	& هشام الغفيلي

● Drugs names   ● Doctors notes   ● Important   ● Extra

« **بأدلاً وسعي** في استنقاذها من الهلاك والمرض، والألم والقلق »

# To understand better

## Peptic ulcer

It is a localized lesion of the mucous membrane of the stomach (gastric ulcer) or duodenum (duodenal ulcer), typically extending through the muscularis mucosa.

### Etiology

***Helicobacter pylori*** is the major etiological factor in peptic ulcer disease (**PUD**).

### Pathophysiology

Imbalance between **aggressive factors** (acid & pepsin) and **defensive factors** (e.g. prostaglandins, mucus & bicarbonate layer). However, nowadays, it seems that ***H. pylori*** theory is very important.

HCl & pepsin → destroy gastric and duodenal mucosa

Mucus and bicarbonate → Protect mucosa

Prostaglandins (PGE<sub>2</sub> & PGI<sub>2</sub>) → Protect mucosa by:

Inhibiting acid secretion, increase mucus & bicarbonate production and enhance mucosal blood flow.

### Risk factors

- ***H. pylori*** infection
- Alcohol
- Smoking
- Caffeine
- Genetic factors
- Diet
- Hypersecretory states (**Zollinger Ellison syndrome**)
- Drugs (e.g. NSAIDs)

## Gastric secretions

### Parietal cells:

HCl & intrinsic factor

### Chief cells:

Pepsinogens

### Mucus secreting cells:

Mucus, Bicarbonate

## Regulation of gastric secretions

**Parietal cells secrete acid in response to:**

**Histamine** (local hormone) → H<sub>2</sub> receptor.

**Gastrin** (hormone): CCK<sub>2</sub> receptors.

**Ach** (neurotransmitter): M<sub>3</sub> receptors.

**Proton pump** (H<sup>+</sup>/ K<sup>+</sup> ATPase).

# Treatment of peptic ulcer

## Treatment of peptic ulcer

**Eradication of *H. pylori* infections**

combination of **metronidazole/clarithromycin** and PPIs

**Hyposecretory drugs**

Proton pump inhibitors

H<sub>2</sub> receptor blockers

Antimuscarinic drugs

Decrease gastric acid secretion  
→ Promote healing & relieve pain.

**Mucosal cytoprotective agents**

Prostaglandin analogues


**Neutralizing agents (antacids)**

Used to relief pain, not a treatment.

## Hypo-secretory drugs

Another helpful diagram-1

Another helpful diagram-2



**Figure 28.4**

Effects of acetylcholine, histamine, prostaglandin E<sub>2</sub>, and gastrin on gastric acid secretion by the parietal cells of stomach. G<sub>s</sub> and G<sub>i</sub> are membrane proteins that mediate the stimulatory or inhibitory effect of receptor coupling to adenylyl cyclase.


Note: Histamine binding causes activation of **adenylyl cyclase**, whereas binding of prostaglandin E<sub>2</sub> inhibits this enzyme. Gastrin and acetylcholine act by inducing an increase in intracellular **Ca<sup>2+</sup>** levels.

# Hypo-secretory drugs

## Proton Pump Inhibitors (PPIs)

**Drug**  
**Omeprazole, Lansoprazole, Pantoprazole, Rabeprazole**

- Mech. of action**
- **Irreversible inhibition of proton pump (H<sup>+</sup>/K<sup>+</sup> ATPase)** (a reactive thiophilic sulfenamide cation, forms a covalent disulfide bond with the H<sup>+</sup>/K<sup>+</sup>-ATPase, irreversibly inactivating the enzyme.)
  - → that is responsible for **final step** in gastric acid secretion from the parietal cell.



- P.D**
- They are **the most potent inhibitors** of acid secretion available today.
  - Produce marked inhibition of basal (released without meal) & meal stimulated-acid secretion (90-98%). → Reduce **pepsin** activity.
  - **Reduce the risk of bleeding from an ulcer caused by aspirin and other NSAIDs.**
  - Promote mucosal healing & decrease pain → Proton pump inhibitors **heal ulcers faster than H<sub>2</sub> blockers**, and have **H. pylori inhibitory properties.**

- P.K**
- Orally, rapidly absorbed from the intestine.
  - Pro-drug, They are **activated** inside the **acidic** medium of parietal cell canaliculi.
  - At **neutral pH**, PPIs are **inactivated**. → Should **not** combined with drugs that **decrease the acidity** (increase stomach's pH): **H<sub>2</sub> blockers** or **antacids**. → because the H<sub>2</sub> antagonists will reduce the activity of the proton pump, and PPIs require active pumps to be effective.
  - Given as **enteric coated formulations** (**unstable** in acidic medium in stomach). → The coating is removed in the **alkaline duodenum**, and the prodrug, a weak base, is absorbed and transported to the parietal cell canaliculus. There, it is converted to the **active form**, which reacts with a cysteine residue of the H<sup>+</sup>/K<sup>+</sup>-ATPase forming a stable covalent bond.
  - Bioavailability is **reduced** by food.
  - Given one half to one hour **before** the meal.
  - Once daily dose is sufficient
  - Metabolized in the liver by **Cyt-P450**.
  - Dose reduction is required in severe **liver failure**.
  - Long duration of action (>12-24h)

- Uses**
- Eradication of H. pylori (combined with **antimicrobial** drugs).
  - **Resistant severe** peptic ulcer ( 4-8 weeks). + **Stress ulcer**.
  - Reflux esophagitis.
  - Hypersecretory conditions as **Zollinger Ellison syndrome\*** and **gastrinoma** → (**First choice**).

1:41 min

- ADRs**
- **CNS**: Headache.
  - **Achlorhydria**. → No HCl at all in the stomach.
  - Hypergastrinaemia. → bc Gastrin levels are regulated by intragastric acidity (high HCl = inhibit gastrin secretion).
  - **Increased bacterial flora**. → Gastric acid is an important barrier to colonization and infection of the stomach and intestine from ingested bacteria.
  - **Long term use (>1 year)**: Vitamin B<sub>12</sub> deficiency (because acid is required for its absorption in a complex with intrinsic factor), Increased risk of **hip fractures** (decrease Ca<sup>2+</sup> absorption).
  - Gastric mucosal hyperplasia.
  - **GIT**: **Diarrhea** & abdominal pain.
  - increased risk of community-acquired respiratory infections & nosocomial pneumonia.

# Hypo-secretory drugs

## H<sub>2</sub> receptor blockers

Drug	Cimetidine, Ranitidine, Famotidine, Nizatidine
MOA	<ul style="list-style-type: none"> <li>Reversibly and competitively block H<sub>2</sub> receptors on the parietal cells.</li> </ul>
P.K	<ul style="list-style-type: none"> <li>Good oral absorption</li> <li>Given <u>before</u> meals.</li> <li>Duration of action (4-12 h).</li> <li>Excreted mainly in urine.</li> <li>Metabolized by liver.</li> <li>Exposed to <b>first pass metabolism</b> (except <b>nizatidine</b> that has the <b>greatest bioavailability</b>)</li> <li><b>Famotidine</b> is the <b>most potent drug</b>.</li> </ul>
P.D	<ul style="list-style-type: none"> <li>❖ Pharmacological actions:           <ul style="list-style-type: none"> <li>Reduce <b>basal</b> and food stimulated-acid secretion.</li> <li><b>Block 90% of nocturnal acid secretion</b> (which depend largely on histamine) &amp; 60-70% of total 24 hr acid secretion. Therefore, it is better to be given <b>before night sleep</b>.</li> <li>Reduce pepsin activity.</li> <li>Promote mucosal healing &amp; decrease pain.</li> </ul> </li> </ul>
Uses	<ul style="list-style-type: none"> <li>GERD (heartburn/ dyspepsia).</li> <li><b>Acute ulcer</b> healing in moderate cases:           <ul style="list-style-type: none"> <li>Duodenal Ulcer (6-8 weeks).</li> <li>Benign gastric ulcer (8-12 weeks).</li> </ul> </li> <li>Pre-anesthetic medication (to prevent aspiration pneumonitis).</li> <li>Prevention of bleeding from stress-related gastritis.</li> <li><b>Post-ulcer</b> healing maintenance therapy.</li> </ul>
ADRs	<ul style="list-style-type: none"> <li><u>GIT disturbances</u>: Nausea &amp; vomiting.</li> <li><u>CNS effects</u>: <b>Headache</b></li> <li><u>Elderly</u>: confusion, hepatic dysfunction, renal dysfunction. → <u>Precautions</u>: Dose reduction of H<sub>2</sub> RAs in <b>severe renal or hepatic failure and elderly</b>.</li> <li>Bradycardia and hypotension (rapid I.V.) → <b>due to blockade of cardiac H<sub>2</sub> R.</b></li> <li><b>CYT-P450 inhibition</b> (Only <b>Cimetidine</b>) decrease metabolism of <b>warfarin, phenytoin, benzodiazepines</b>. → thus potentiate the action → <u>Pic explains</u></li> <li><u>Endocrine effects</u> (<b>Only Cimetidine</b>):           <ul style="list-style-type: none"> <li><b>Galactorrhea</b> (Hyperprolactinemia) → <b>Infertility in female</b>.</li> <li><b>Antiandrogenic actions</b> (gynecomasteia – impotence) due to inhibition of <b>dihydrotestosterone</b> binding to androgen receptors.</li> </ul> </li> </ul>
precaution	<ul style="list-style-type: none"> <li>Although there are no known harmful effects on the fetus, H<sub>2</sub> antagonists cross the placenta. Therefore, they should not be administered to <b>pregnant women</b> unless absolutely necessary. The H<sub>2</sub> antagonists are <b>secreted into breast milk</b> and may therefore affect nursing infants. (<u>Pregnant &amp; breast feeding women</u>)</li> <li>Liver disease.</li> </ul>

# Hypo-secretory drugs

	Cimetidine	Ranitidine	Famotidine	Nizatidine
<b>Efficacy</b>	+++	+++	+++	+++
<b>Potency</b>	+	++	+++	++
<b>Dose</b>	400 mg bid	150 mg bid	<b>20</b> mg bid	150 mg bid
<b>Rout</b>	PO, IV	PO, IV	PO, IV	PO, IV
<b>T<sub>1\2</sub></b>	Short (2h)	Longer (3h)	Longer (3h)	Shortest (1h)
<b>Duration</b>	5-6 h	10 h	12 h	11 h
<b>CYT P 450</b>	++	-	-	-
<b>Antiandrogenic</b>	++	-	-	-
<b>Drug interaction</b>	Many	No	No	No

What is the difference between the efficacy & potency?

- Efficacy = All the drugs are effective in reducing HCl.
- Potency = Depends on one thing, the conc. of the drug  
→ The lowest conc. = The highest effect. → e.g. Famotidine.

## Prostaglandin analogues (PGE<sub>1</sub>) → Misoprostol

<b>MOA</b>	<ul style="list-style-type: none"> <li>○ <b>Lowers HCl secretion.</b></li> <li>○ Increase the protective measures → (↑ mucous / bicarbonate &amp; gastric mucosal blood flow).</li> <li>○ <b>PGE<sub>1</sub> &amp; PGI<sub>2</sub></b> → have cyto-protective mechanism on the stomach.</li> </ul>
<b>P.K</b>	<ul style="list-style-type: none"> <li>○ Orally, must be taken 3-4 times\day.</li> </ul>
<b>Uses</b>	<ul style="list-style-type: none"> <li>○ <b>Used for NSAIDs-induced peptic ulcer.</b> → bc non-specific NSAIDs inhibit prostaglandins. that's why nowadays they produce selective COX-2 inhibitors.</li> </ul>
<b>ADRs</b>	<ul style="list-style-type: none"> <li>○ <b>Abdominal cramps; diarrhea.</b> → prostaglandins increase GIT motility.</li> <li>○ <b>Uterine contraction</b> (dysmenorrhea or abortion), <b>dislodging of the fetus</b></li> <li>○ Vaginal bleeding.</li> </ul>
<b>C.I</b>	<ul style="list-style-type: none"> <li>○ <b>Pregnancy.</b></li> </ul>

# Antacids

MOA	<ul style="list-style-type: none"> <li>These drugs are mainly <b>inorganic salts</b> e.g. <math>\text{NaHCO}_3</math>; <math>\text{CaCO}_3</math>; <math>\text{Al}(\text{OH})_3</math>; <math>\text{Mg}(\text{OH})_2</math>.</li> <li>Acts by <b>direct chemical neutralization of HCL</b> (No receptors action) and as a result may decrease pepsin activity → Because pepsin is inactive at a pH greater than 4.</li> </ul>
P.K	<ul style="list-style-type: none"> <li><b>All</b> antacids ↓ absorption of some drugs as <b>tetracycline</b>, <b>fluoroquinolones</b>, iron.</li> </ul>
Use	<ul style="list-style-type: none"> <li>Used to relief pain of peptic ulcer &amp; for dyspepsia.</li> </ul>
ADRs	<ul style="list-style-type: none"> <li><b><math>\text{NaHCO}_3</math> (sodium bicarbonate)</b>: Effective, but systemic alkalosis may occur, <b>contraindicated in CVS patients</b>.</li> <li><b><math>\text{CaCO}_3</math> (Calcium carbonate)</b>: <b>Milk alkali syndrome</b>. (<u>hypercalcemia</u>, renal failure)</li> <li><b><math>\text{Al}(\text{OH})_3</math> (Aluminum hydroxide)</b>: <b>constipation</b>, Systemic phosphate depletion → The binding of phosphate by aluminum-containing antacids can lead to hypophosphatemia (weakness, malaise, anorexia)</li> <li><b><math>\text{Mg}(\text{OH})_2</math>: Diarrhea</b>, Magnesium trisilicate - slow-acting antacid. → so mixtures of latter two can, happily, be used to preserve normal bowel function</li> </ul>

## Quick summary

### Treatment of peptic ulcer

#### *H. pylori*

Test for *H. pylori* prior to beginning therapy.

Complete *H. pylori* eradication is required to prevent relapse.

PUD\* with *H. pylori* infections can be treated with triple therapy or quadruple therapy.

**Acid reducing medications** → in case of PUD without *H. pylori* infections.

**H2 receptor antagonist.**

**PPI's** should be used for:

- **Acute** therapy **only** if H2RAs **fail** or cannot be used
- As part of treatment for *H. pylori*.

\* Peptic ulcer disease

# Summary-1

## Treatment of peptic ulcer

1- Eradication of *H. pylori* infections.  
→ **Metronidazole** + **clarithromycin** and **PPIs**.

3- Mucosal cytoprotective agents.

2- Hyposecretory drugs

4- Neutralizing agents (antacids)

### Hyposecretory drugs

#### Proton Pump Inhibitors (PPIs)

#### H<sub>2</sub> receptor blockers (H<sub>2</sub>RAs)

Drug

**Omeprazole**, **Lansoprazole**,  
**Pantoprazole**, **Rabeprazole**

**Cimetidine**, **Ranitidine**,  
**Famotidine**, **Nizatidine**

MOA

Irreversible inhibition of proton pump (H<sup>+</sup>/K<sup>+</sup> ATPase).

Reversibly and competitively block H<sub>2</sub> receptors on the parietal cells.

P.D

- The most potent inhibitors of acid secretion.
- Marked inhibition of basal & meal stimulated-acid secretion.
- Reduce pepsin activity.
- Promote mucosal healing & decrease pain.

- Reduce basal and food stimulated-acid secretion.
- Block 90% of **nocturnal** acid secretion → better to be given before night sleep.
- ↓ Pepsin activity.
- Promote mucosal healing & decrease pain.

P.K

- Oral, rapidly absorbed from the intestine.
- Activated inside acidic medium of parietal cell canaliculi → Inactive in neutral pH.
- Not combined w\ H<sub>2</sub>RAs or anacids.
- Bioavailability is reduced by food.
- Long duration of action.
- Reduce dose with sever liver failer.

- Good oral absorption.
- Giver before meals.
- Metabolized by liver.
- Exposed to 1<sup>st</sup> pass metabolism except **Nizatidine** (has the greatest bioavailability)
- **Famotidine** is the most potent drug.

Uses

- **Eradication of *H. pylori***.
- Resistant severe peptic ulcer.
- Reflux esophagitis.
- 1<sup>st</sup> choice with hypersecretory condition e.g. **Zollinger Ellison syndrome** and gastrinoma.

- GERD.
- Acute ulcer healing in moderate cases
- Pre-anesthetic medication (to prevent aspiration pneumonitis).
- Prevention of bleeding from stress-related gastritis.
- Post-ulcer healing maintenance therapy.

ADRs

- Headache.
- Achlorhydria.
- Diarrhea.
- Hypergastrinaemia.
- ↑ bacterial flora.
- Risk of respiratory infection.
- Long use: ↓ Vit.B12 , ↑ hip fracture.

- Nausea & vomiting.
- Headache & confusion.
- Hepatic dysfunction & renal dysfunction → Elderly.
- Bradycardia and hypotension (rapid I.V.).
- Only **Cimetidine** ADRs:
  - CYT-P450 inhibition.
  - Galactorrhea.
  - Antiandrogenic actions.



# Summary-2

Antacids		Prostaglandin analogues (PGE1) → Misoprostol
MOA	<ul style="list-style-type: none"> <li>- They are mainly <b>inorganic salts</b> e.g. <math>\text{NaHCO}_3</math>; <math>\text{CaCO}_3</math>; <math>\text{Al}(\text{OH})_3</math>; <math>\text{Mg}(\text{OH})_2</math>.</li> <li>- Direct chemical neutralization of HCL and as a result may decrease pepsin activity.</li> </ul>	<ul style="list-style-type: none"> <li>- <b>Lowers HCL secretion.</b></li> <li>- Increase the protective measures.</li> </ul>
P.K	<b>All antacids ↓</b> absorption of some drugs as <b>tetracycline</b> , <b>fluoroquinolones</b> , iron.	Orally, must be taken 3-4 times\day
Uses	Used to relief pain of peptic ulcer & for dyspepsia.	<b>Used for NSAIDS-induced peptic ulcer.</b>
ADRs	<ul style="list-style-type: none"> <li>- <b><math>\text{NaHCO}_3</math></b>: Systemic alkalosis.</li> <li>- <b><math>\text{CaCO}_3</math></b>: milk alkali syndrome. (hypercalcemia, renal failure)</li> <li>- <b><math>\text{Al}(\text{OH})_3</math></b>: constipation.</li> <li>- <b><math>\text{Mg}(\text{OH})_2</math></b>: Diarrhea.</li> </ul>	<ul style="list-style-type: none"> <li>- Abdominal cramps; diarrhea</li> <li>- <b>Uterine contraction</b> (dysmenorrhea or abortion); vaginal bleeding.</li> </ul>

## Clinical use of agents affecting gastric acidity



- Histamine  $\text{H}_2$  receptor antagonists (e.g. **ranitidine**):
  - *peptic ulcer*
  - *reflux oesophagitis*.
- Proton pump inhibitors (e.g. **omeprazole**, **lansoprasole**):
  - *peptic ulcer*
  - *reflux oesophagitis*
  - as one component of therapy for *Helicobacter pylori* infection
  - *Zollinger–Ellison syndrome* (a rare condition caused by gastrin-secreting tumours).
- Antacids (e.g. **magnesium trisilicate**, **aluminium hydroxide**, **alginates**):
  - *dyspepsia*
  - symptomatic relief in *peptic ulcer* or (*alginate oesophageal reflux*).
- **Bismuth chelate**:
  - as one component of therapy for *H. pylori* infection.

# MCQs

**1- Patient has Gastrin-secreting tumor of the pancreas which one of the following is the proper treatment?**

- A- Cimetidine
- B- Misoprostol
- C- Omeprazole
- D-  $\text{NaHCO}_3$

**2- Patient was prescribed a drug for heartburn, later he complained of sexual dysfunction. what was the drug?**

- A- Omeprazole
- B- Cimetidine
- C- Nizatidine
- D- Famotidine

**3- Medical student complained of stress related gastritis. Which one of the following drugs can be used to prevent bleeding?**

- A- Misoprostol
- B-  $\text{CaCO}_3$
- C- Rappazole
- D- Famotidine

**4- Patient was taking medication for back pain for a long time, later he developed an epigastric pain, nausea and vomiting. Which one of the following is the underlying cause?**

- A- Inhibit synthesis of gastrin
- B- Inhibit synthesis of leukotrienes.
- C- Inhibit synthesis of prostaglandins
- D- Inhibit synthesis of COX-2

**5- Which one of the following inorganic salts may develop milk alkali syndrome?**

- A-  $\text{Mg}(\text{OH})_2$
- B-  $\text{Al}(\text{OH})_3$
- C-  $\text{NaHCO}_3$
- D-  $\text{CaCO}_3$

**6- Which inorganic salt can cause diarrhea?**

- A-  $\text{Mg}(\text{OH})_2$
- B-  $\text{Al}(\text{OH})_3$
- C-  $\text{NaHCO}_3$
- D-  $\text{CaCO}_3$

---

**Thank you for checking our team!**

---



---

Pharmacology 435

 @pharmacology435

### Sources:

1. 435's slides.
2. Pharmacology (Lippincotts Illustrated Reviews Series), chapter 28, 5<sup>th</sup> edition.
3. Basic & Clinical Pharmacology by Katzung, chapter 62, 12<sup>th</sup> edition.
4. Rang & Dale's pharmacology, chapter 29, 7<sup>th</sup> edition.